Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 16/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 10/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 11/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4833890 | 0.83 | NAMPT (0.48) | MAPTTDP1ALDH1A1KDM4EMCL1 | |
| SCHEMBL1749697 | 0.81 | MAPT (0.52) | MAPTTDP1ALDH1A1KDM4EMCL1 | |
| SCHEMBL1749694 | 0.81 | MAPT (0.52) | MAPTTDP1ALDH1A1KDM4EMCL1 | |
| SCHEMBL1751383 | 0.77 | MAPT (0.52) | MAPTTDP1ALDH1A1KDM4EMCL1 | |
| SCHEMBL1751385 | 0.77 | MAPT (0.52) | MAPTTDP1ALDH1A1KDM4EMCL1 | |
| SCHEMBL27197486 | 0.75 | CHIT1 (0.47) | MAPTTDP1ALDH1A1KDM4EMCL1 | |
| SCHEMBL1749531 | 0.75 | MAPT (0.44) | MAPTTDP1ALDH1A1KDM4EMCL1 | |
| SCHEMBL1750407 | 0.74 | MAPT (0.49) | MAPTTDP1ALDH1A1KDM4EMCL1 | |
| SCHEMBL14905666 | 0.74 | EPHX2 (0.61) | MAPTTDP1ALDH1A1KDM4EMCL1 | |
| SCHEMBL4838158 | 0.73 | MCHR1 (0.52) | USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299104-B2 | Melanin hormone antagonist; therapy for obesity, type-2 diabetes | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-10-30 | — | — | US | disclosed |
| US-20080207707-A1 | ARYL-SUBSTITUTED HETEROCYCLES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-08-28 | — | — | US | disclosed |
| US-7319108-B2 | Aryl-substituted heterocycles, process for their preparation and their use as medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-01-15 | — | — | US | disclosed |
| US-20050176710-A1 | Aryl-substituted heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207707-A1 | ARYL-SUBSTITUTED HETEROCYCLES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | CYP11B1, CYP11B2, GPR119 | MAPT 4828/4885TDP1 4363/4885ALDH1A1 406/4885 |
| US-20050176710-A1 | Aryl-substituted heterocycles, process for their preparation and their use as medicaments | CYP11B1, CYP11B2, GPR119 | MAPT 4828/4885TDP1 4363/4885ALDH1A1 406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.